The FDA escalated its effort to remove Tavneos (amgen) from the market, alleging trial manipulation that tainted the data supporting approval. The agency’s action adds a new layer of regulatory scrutiny to rare-disease approvals and signals a willingness to unwind products when it identifies issues tied to underlying evidence. For biotech companies, the Tavneos decision raises the compliance bar around clinical trial conduct and data integrity, particularly in pivotal studies used for expedited pathways. It also intensifies attention on sponsor communication during agency review and post-approval surveillance. Amgen said it would not voluntarily withdraw the product, disputing the FDA’s characterization and arguing the drug is safe. That disagreement suggests a potentially prolonged post-market fight, with implications for patients, payer coverage, and future submissions built on similar evidentiary structures. Overall, the move underscores that even years after approval, the FDA can revisit and challenge the factual basis for marketing authorization when new information emerges.